Studying the influence of curcumin and piperine on tamoxifen exposure
Completed
- Conditions
- Breast cancer
- Registration Number
- NL-OMON25193
- Lead Sponsor
- Erasmus MC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 16
Inclusion Criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
1. Age > 18 years
Exclusion Criteria
A potential subject who meets any of the following criteria before study treatment will be excluded from participation in this study:
1. Pregnant or lactating patients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the influence of curcumin with or without piperine, in patients with breast cancer, on endoxifen plasma pharmacokinetics (AUC).
- Secondary Outcome Measures
Name Time Method 1. Other pharmacokinetic outcomes (i.e. clearance, Ctrough) and the tamoxifen/endoxifen ratio.<br /><br>2. To evaluate plasma concentration levels of tamoxifen and other tamoxifen metabolites<br /><br>3. To evaluate the incidence and severity of side-effects of treatment with tamoxifen in absence and presence of curcumin with or without piperine.